Obsidian Therapeutics Announces Novel OBX-115 Therapy for Advanced Melanoma Treatment
Obsidian Therapeutics announced that the U.S. FDA has granted Fast Track Designation for OBX-115. This innovative engineered tumour-derived autologous T-cell immunotherapy, also known as tumour-infiltrating lymphocyte (TIL) cell therapy, is designed with a pharmacologically regulatable membrane-bound IL15 (mbIL15).
It is intended for patients with metastatic or locally advanced melanoma who have not responded to, or have relapsed after, PD-1/PD-L1 immune checkpoint inhibitors (ICIs).
The Fast Track Designation highlights the significant unmet need for patients whose melanoma has progressed following ICI therapy, regardless of their mutational status. OBX-115 aims to meet this need and is seen as a potential game changer in treatment. Its design allows for compatibility with core needle biopsy tumour tissue procurement and is associated with a safer and more tolerable profile compared to traditional non-engineered TIL cell therapies.
This role is anticipated to promote continued partnership with the FDA as Obsidian progresses with the clinical development of OBX-115 in the post-ICI context.
Fast Track Designation aims to streamline the development and review of new drug candidates targeting serious or life-threatening conditions, ensuring that approved products can be brought to market more quickly. Key features of this designation include regular interactions with the FDA review team and, if specific criteria are met, eligibility for Priority Review and Rolling Review.
OBX-115 is currently undergoing a multicenter trial aimed at advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) (NCT06060613). Enrollment for the first-in-human, single-center study of OBX-115 (NCT05470283) has been completed.
OBX-115 aims to improve the persistence, anti-tumour activity, and clinical safety of TIL cell therapy. The treatment is presently being studied in two active clinical trials targeting advanced or metastatic melanoma and non-small cell lung cancer (NSCLC).
